Complete gig history
All talks by Greg Williams
7 talks·2 with video·2 years
Loading talks…
AI, quantum simulation, and synthetic biology are accelerating drug discovery in ways that were impossible just a few years ago - compressing timelines, expanding what’s scientifically feasible, and opening new paths for treating unmet medical needs. As these technologies move from research to real-world impact, regulators, developers, and the public face new questions around evaluation, trust, and access. This panel explores how we can modernize oversight, build confidence in AI-enabled science, and ensure that faster innovation translates into broader patient benefit.
Seeing is no longer believing. With a simple prompt, anyone can now create images, sounds or videos that appear perfectly convincing. Newsrooms, HR departments, cybersecurity firms and all of us going about our daily lives are all hitting the same wall: we need to find new ways to verify real-looking media that can be generated in seconds. How can we move towards a "provenance-first" culture, where the origin of media matters as much as the content itself? What guardrails, from digital watermarking to human verification policies, can companies and regulators adopt? And as the technology evolves, what happens to our legal and social systems when evidence can no longer be taken at face value?
From hospitals to homes, social robots are entering everyday care, supporting patients, assisting caregivers, and helping manage tasks from monitoring to rehabilitation. But what happens to trust, empathy, and human connection when machines take on these roles? Can they ease workforce shortages and improve quality of care without replacing essential human judgment? This session explores how these technologies are reshaping care and what it will take to integrate them responsibly.
Europe has talent, capital, and ambition, yet its most promising startups still struggle to scale, or leave. Somewhere between early growth and global scale, momentum is lost. Why? The reasons are debated: fragmented markets, regulatory complexity, access to capital. New ideas like the 28th regime aim to simplify this path and reduce friction across borders. Yet the question remains whether structural change can keep up with the speed at which companies need to grow. Is Europe solving the right problem? And what would it take to turn a strong startup ecosystem into a true scale-up economy?